Technology Transfer

Technologies protected in 2021


Applications filed


Xavier Barril
  • Compounds for use in the treatment of hyperproliferative disorders.
Julio Lloret
  • Method of Preparation of Electrodes for Electrocatalysis
Morgan Mitchell
  • Undisclosed title
Víctor Puntes
  • Ophthalmic topical composition with ceria nanoparticles for treating diseases of posterior segment of the eye
Xavier Salvatella
(IRB Barcelona)
  • Compounds and their use in a method for modulating AR (Androgen receptor) transcriptional activity
Antonio Acín
  • Undisclosed title
Giuseppe Battaglia

  • Polymersomes for Clearance of Amyloid-Beta and/or Tau
Jordi Cabot
  • Plataforma Xatkit + know-how
 Turgut Durduran
  • Undisclosed title
Jose Antonio Garrido
  • A flexible probe
  • Neurostimulation system for Deep Brain Stimulation
Daniel Maspoch
  • Antimicrobial composite material
Josep Nogués
  • Method for manufacturing an emitter for electrospray generators
Valerio Pruneri
  • A method to increase permeability of membranes for fluids using short chain polymers
  • Undisclosed titles (3)
Jelena Radjenovic
  • Method to prepare an electrode with a manganese oxide coated titanium oxide nanotube array interlayer, electrode obtained thereof, and uses of the electrode
Albert Tarancón
  • Electronic Transistors
  • An integrated single 3D printing system-based process for manufacturing a monolithic solid oxide cell (SOC) stack
Joaquín Arribas
  • The role of PD-L2 in ageing
Salvador Aznar Benitah
(IRB Barcelona)
  • CD36 Inhibitor for use in promoting muscle regeneration
Josep Dalmau
  • Method and reagents for the detection of an autoantibody
Manel Esteller
  • Markers of prediction of response to CART cell therapy
Pau Gorostiza
  • License agreement signed with an international life chemical dealer for the worldwide commercialization of one of the molecules developed in our lab. The molecule is commercialized as a pharmacological tool
Josep M. Llovet
  • Method and reagents for the detection of an autoantibody
Javier Martínez Picado
  • Siglec-1 inhibitors for preventing, inhibiting the progression or treating Coronavirus infections
  • Method for detecting and quantifying inducible HIV reservoirs
Pura Muñoz
  • CD36 Inhibitor for use in promoting muscle regeneration
Antonio Postigo
  • Cancer informative biomarker signature
Natasa Przulj
  • Know-how of biomedical data fusion for precision medicine
Luis Serrano
  • Tools and Methods for Mycoplasma Engineering
  • Attenuated Mycoplasma Bacteria
  • Genetically reprogrammed Mycoplasma bacteria and uses thereof
  • Genetically modified Mycoplasma bacteria active against heterogeneous bacterial biofilms
Isabelle Vernos
  • Inhibitors of microtubule polyglutamylation in mitosis for use as a medicament

Science to Society – ERC Proof of Concept grants

The ERC Proof of Concept Grants aim to maximise the value of the excellent research that the ERC funds, by funding further work (i.e. activities which were not scheduled to be funded by the original ERC frontier research grant) to verify the innovation potential of ideas arising from ERC funded projects. Proof of Concept Grants are therefore on offer only to Principal Investigators whose proposals draw substantially on their ERC funded research.


active grants in 2021

Jens Biegert · miniX - MINIaturitzed coherent soft X-ray source for research and industry

X-rays are a prime analytical tool across a diverse range of areas in our modern economy—from fundamental physics and chemistry research, to the pharmaceutical and semiconductor industries. In particular, sources of ultrafast coherent x-rays are expected to have a transformative impact in all of these areas due to their capacity to enable the study of interactions between charge carriers and atoms in gases, liquids and solids, in real-time, and with element specificity. Ease of use, compactness and price will prove vital for any new X-ray technology looking to find use in industrial applications. “miniX” will address all of these issues with the miniaturization of a laser-based soft x-ray source, designed for lay user operation and at low cost.

Jens BiegertInstitut de Ciències Fotòniques (ICFO)
ERC – PoC2018

Daniel Maspoch · Hybead - Hybrid Bead Adsorbents

HybeadHybrid Bead Adsorbents

Each year, millions of people, most of them children, die from diseases associated with inadequate water supply, sanitation and hygiene. In particular, exposure to heavy metals in drinking water, even at trace levels, poses a considerable health risk. As included in one of the seventeen sustainable development goals of the United Nations, “safe water and adequate sanitation are indispensable for healthy ecosystems, reducing poverty, and achieving inclusive growth, social well-being and sustainable livelihoods”. In this PoC project, named Hybrid Bead Adsorbents (Hybead), we aim to evaluate the feasibility of advancing Hybrid Inorganic Nanoparticle/Metal-Organic Frameworks Bead-type adsorbents into the pre-commercial stage, with the aim of accelerating their access to the market as an efficient technology for removing heavy metal ions from water. The first part of Hybead encompasses scaling-up of our current spray-drying synthesis of these beads from the gram-scale to economically viable kilogram-scale production. We will also shape the composite beads for proving its use into existing water purification technologies. This will entail shaping Hybead into granules and integrating them as fillers into polymer matrices to produce membranes by common industrial-scale methods (e.g. compaction and solvent casting). The second part of Hybead will be dedicated to intellectual property (IP) and market aspects needed for the pre-commercialization of this new technology for water purification. This study will include a patentability study, a freedom-to-operate (FTO) analysis and a market study to identify the filter producers that could ultimately serve as manufacturing partners. In this project we will endeavor to assess the commercial viability of with Hybead adsorbents, accelerate their market entry and ultimately, explore the possibility of launching a spin-off to manufacture and commercialize viable products.

Daniel MaspochInstitut Català de Nanociència i Nanotecnologia (ICN2)
ERC – PoC2019

Paolo Melchiorre · Light-COAT - Visible Light-Activated Photoinitiators for Applications in Domestic Coatings

Light-COAT – Visible Light-Activated Photoinitiators for Applications in Domestic Coatings

The use of light to trigger and control radical polymerisation is a powerful strategy for rational polymer synthesis and advanced materials. Photoinitiated polymerisation is today widely used in industry for several applications. Essential for the continued progress of the field is the discoveries of novel photoinitiators endowed with tailored properties, such as high activity at ambient temperature and the possibility to use visible light instead of UV irradiation to produce radicals in high quantum yields. Using visible light is essential for domestic applications, as there would be no hazards related to exposure to UV light. Light-COAT aims at preparing new visible-light-activated photoinitiators and evaluate their potential for the formulation of domestic coating compositions. As part of the ERC-2015-CoG project CATA-LUX (681840), focused on developing photochemical synthetic methodologies, we recently identified a family of visible-light-absorbing organic compounds with high potential to act as photoinitiators for polymer applications. These photoinitiators can be easily synthesised, are activated by weak light, including solar light or simple light-emitting-diodes, provide access to colourless polymeric materials, and have shown potential for applications in domestic indoor/outdoor coatings. These unique features make this novel family of photoinitiators suitable to enhance convenience in use (reduced drying time and improved weatherproof feature), offering a strong opportunity to improve domestic coating formulations.

Paolo Melchiorre – Institut Català d’Investigació Quimica (ICIQ)
ERC – PoC2019

Pablo Menéndez · IT4B-ALL - Therapeutic immunotherapy targeting NG2 and CD22 antigens for MLL-rearranged and MLL-germline B-cell Acute Lymphoblastic Leukemia

IT4B-ALL – Therapeutic immunotherapy targeting NG2 and CD22 antigens for MLL-rearranged and MLL-germline B-cell Acute Lymphoblastic Leukemia

B-ALL is the commonest cancer of childhood. There remain childhood B-ALL subgroups with dismal prognosis such as infant B-ALL and B-ALL carrying MLL rearrangements (MLLr). In addition, the prognosis of adult B-ALL is worse, and refractory/relapse (R/R) B-ALL remains dismal. CD19-targeted immunotherapies have emerged as promising therapeutic approaches for R/R B-ALL. CD19 CAR T-cells have shown impressive efficacy in R/R B-ALL. However, relatively rapid relapses are frequently observed, a proportion of them losing CD19 expression upon CAR19 T-cell therapy due to massive antigen pressure over CD19, resulting in a myeloid lineage switch in MLLr B-ALL, or the selection of CD19-/CD34+ preleukemic progenitors. Further CD19-targeted therapy is thus ineffectual for CD19neg R/R B-ALL. Our overarching goal is to provide novel therapeutic options for (R/R) B-ALL.Targeting surface antigens whose expression, opposite to CD19, are commonly retained at relapse is a valid strategy to circumvent the loss of CD19 found in (R/R) B-ALL after CD19-targeted therapies. Recent work funded by my ERC-2014-CoG has identified NG2 and CD22 as key antigens to be targeted in (R/R) B-ALL. First, both antigens are retained in CD19neg R/R B-ALL. Second, NG2 is solely expressed in MLLr B-ALL, and is associated with CNS infiltration, aggressiveness and glucocorticoid resistance. Third, CD22 is a pan-B marker expressed developmentally earlier than CD19, and CD34+CD22+CD19- cells may represent pre-malignant progenitors escaping the CD19-targeted pressure. These results have just been protected by a European Patent (EPI173825514), and are the proof-of-principle demonstration of NG2 & CD22 representing promising immunotherapeutic targets, when combined with CD19 for both MLLr & MLL-germline B-ALL, respectively. Here we propose to consolidate preclinical work and GMP production of anti-NG2 monoclonal antibody and NG2/CD19 and CD22/CD19 CAR T-cells to launch a PhaseI academic clinical trial for R/R B-ALL.

Pablo MenéndezInstitut Josep Carreras (IJC)
ERC – PoC2018

Natasa Przulj · GENETTA - Genomic Data-Fusion Platform for Omics-Driven Precision Medicine

GENETTA – Genomic Data-Fusion Platform for Omics-Driven Precision Medicine
This PoC project aims to pave the road to commercialize a comprehensive data analytics platform enabling data-driven biomedical innovation and precision medicine. The platform is specifically designed to efficiently fuse and mine heterogeneous omic data, including genomes, epigenomes, proteomes, metabolomes, patient clinical profiles, drugs and their chemical similarities, disease and other ontologies, and other relevant omic data. The goal of this development is to provide the most advanced software platform for fusion and analytics of numerous heterogeneous multi-scale omic data that takes advantage of novel non-negative matrix trifactorization (NMTF)-based and network mining algorithms, providing dramatic improvements in the number and type of fused data, quantity of data, computational efficiency and biomedical accuracy compared to the most advanced omic data analytics platforms currently existing. The main goal of the PoC is to close the gap between the research results of ERC Consolidator Grant, ICON-BIO, and the production of a commercial data analytics platform for the bio-pharmaceutical sector. In particular, the solution will target biopharma companies to embed the platform into their existing Data Science resources and enable effective and efficient application of the platform’s explainable AI methods (resulting from ICON-BIO) to optimize and guide their discovery processes. The result of this effort will be the achievement of a market-ready Data Analytics Platform.

Natasa PrzuljBarcelona Supercomputing Centre – Centro Nacional de Supercomputación (BSC – CNC))
ERC – PoC2020

Victoria Reyes García · ICCION - Indigenous Climate Change Impacts Observation Network

 ICCION – Indigenous Climate Change Impacts Observation Network
The Local Indicators of Climate Change Impacts project (771056-LICCI-ERC-2017-COG) explores the potential of Indigenous and local knowledge (ILK) to contribute to climate research, but only tangentially addresses the marginalized position faced by Indigenous Peoples and local communities (IPLC) to bring their knowledge and perspectives to climate change research and policy fora. This PoC will bring IPLC knowledge and perspectives to climate change research and policy fora by 1) engage with IPLC on the co-design of a digital Indigenous Climate Change Impacts Observation Network (ICCION) and 2) engaging with the Local Communities and Indigenous Peoples Platform (LCIPP) of the UNFCCC, which has the mandate to strengthen IPLC knowledge and efforts related to addressing and responding to climate change. ICCION holds social, political, and technological innovative potential. The creation of an Indigenous Climate Change Impacts Observation Network is an innovative response to the IPCC call for more ground level data, as it will bring expand the geographical and temporal coverage of data collection on local indicators of climate change impacts. Moreover, partnering with IPLC and international organizations constitutes an important social innovation, as these alliances might facilitate the process of establishing a continuous, iterative, and bidirectional dialogue that foster IPLC effective participation in climate change science-policy fora. Finally, ICCION innovates in developing technological solutions to address technical (i.e., low internet access) and social concerns (i.e., Indigenous data sovereignty) that are of particular relevance for IPLC, but which have often been neglected in other technological developments. The long-term establishment of the observation network proposed here will contribute to give IPLC a more relevant voice in global climate policy fora, not only by informing climate change impact research, but also making it more socially acceptable.

Victoria Reyes García – Universitat Autònoma de Barcelona (UAB)
ERC – PoC2019

Neus Sabaté · POWER-PATCH - Self-Powered Skin Patch for Cystic Fibrosis Diagnosis

POWER-PATCH – Self-Powered Skin Patch for Cystic Fibrosis Diagnosis
Cystic fibrosis (CF) is a genetic autosomal recessive disease, which induces mutations on a conductance transmembrane regulator protein (CFTR) that controls the exocrine system responsible or producing saliva, sweat, tears and mucus. The protein malfunction affects severely the lungs and digestive system. Patients with CF present also higher chloride contents in sweat than healthy subjects, so chloride testing in sweat has become the gold standard test for CF confirmation after new-born screening blood tests. However, tests on new-borns are not 100% sensitive and not universally stablished along European territory, which leads to patients with a late diagnostic that decreases their life quality and expectancy. The ‘sweat test’ requires either sophisticated analytical procedures or costly commercial analyzers and consumables that restrict the availability of the test to few specialized units scattered along the European territory. POWER-PATCH aims to evolve and promote the value of a novel, market disruptive patch that enables an affordable and easy-to-use sweat test for the screening of cystic fibrosis. The patch has been conceived to be applied on the forearm of the patient and yield a “positive” result in case of an abnormal conductivity level of sweat is detected. It combines the low cost and easy handling of paper that is associated with the filter paper-based diagnosis technique and at the same time allows obtaining a digital response with no further handling or treatment of the sample. Moreover, as it already contains a “battery sensor”, sweat collection and testing does not require additional equipment and can be easily taken to any clinical environment. Within this ERC PoC project, we aim to achieve (i) Technical validation and Clinical testing in a specialized CF unit and (ii) a business proposition in the form of a Business Plan containing strategies for commercialization, fundraising, IP management and future product development.

Neus SabatéInstitute of Microelectronics of Barcelona – Centre Nacional de Microelectónica (CSIC – IMB-CNM)
ERC – PoC2019

Manuel Serrano · SENFIB - Novel senolytic drugs for the treatment of lung and kidney fibrosis

SENFIB – Novel senolytic drugs for the treatment of lung and kidney fibrosis
SENFIB aims to deliver new drugs for the treatment of fibrotic diseases. Nearly one quarter of the global population will be over the age of 65 by 2050. Populations over 65 suffer from multiple degenerative diseases including tissue fibrosis, estimated to account for upwards of 45% of all-cause mortality. Animal models have demonstrated that senescent cells are causative in many fibrotic diseases including lung (i.e. idiopathic pulmonary fibrosis, IPF), and chronic kidney disease (CKD). Senescent cells have experienced damage or stress and have permanently exited the cell cycle, yet remain viable and long-lived, generating a persistent, sterile inflammation. Selective elimination of senescent cells in animal models of IPF, CKD, and aging demonstrated improved organ function and viability. Senolytics, molecules that induce preferential killing of senescent cells while leaving healthy cells intact, have emerged as a promising approach for tackling age-associated diseases; this was named one of the “10 Breakthrough Technologies” of 2020 by the MIT Technology Review. Thus far, few senolytics have been identified; their mode of action is often unknown, some present serious toxicities, and none has yet been demonstrated to have therapeutic activity in clinical trials. We propose to launch a drug discovery program based on a prioritized novel genetic target for senolysis, which we have already validated as senolytic using a tool compound in an in vivo model of IPF. We will deliver a lead series of molecules with IPR that meet all typical drug requirements plus in vivo Proof-of-Concept data in different mouse models of IPF and CKD. The ultimate goal of this project is to develop candidates for translation into clinical use to ameliorate fibrotic diseases via the selective elimination of senescent cells.

Manuel Serrano – Institut de Recerca Biomèdica (IRB Barcelona)
ERC – PoC2020

Jordi Sort · MAGIC-SWITCH: Magnetic Switch Controlled with Voltage

MAGIC-SWITCH Magnetic Switch Controlled with Voltage
We are living in a world that is increasingly driven by data. Governments, healthcare facilities, commercial businesses and individuals are all storing information in electronic form. This has led to the emergence of digital and cloud-based technologies. The ability to use information more efficiently has resulted in a rapid increase of the value of information. However, with the Big Data revolution, information is facing new challenges. Energy efficiency during writing of magnetic information needs to be improved. Thus, enhancing robustness in data storage systems is one of the major challenges in our modern society. Our vision for the near future is to turn the scientific output of the ERC Consolidator SPIN-PORICS into a new type of storage memory. MAGIC-SWITCH will deliver the prototype and business case for a new type of compact storage memory, at an industrial-relevant scale. The specific goal of this PoC project is to take the initial steps towards this vision by building a prototype (moving from Technology Readiness Level TRL 3 to 5), standardizing its manufacturing process and creating a business case for its commercial exploitation (including a pitch that can be used to close new partnerships or in fund-raising).

Jordi Sort – Universitat Autònoma de Barcelona (UAB)
ERC – PoC2019

Sergio Valenzuela · SOTMEM - Topological Insulator-Based Spin Orbit Torque MEMories

SOTMEM – Topological Insulator-Based Spin Orbit Torque MEMories
SOTMEM addresses the growing need for scalable ultrafast non-volatile memories (NVM) to improve the reliability of logic circuitry and to reduce the ever increasing power consumption and energy loss in microprocessors. Major technology actors and end-user companies are developing magnetic RAM (MRAM) as it is recognized as one of the most promising emerging NVMs. However, mainstream MRAM, relying on spin transfer torque, suffers from limited speed, and reliability and degradation issues. These three obstacles, which impede the widespread implementation of MRAM, can be mitigated using a novel device architecture based on spin-orbit torque (SOT). But even SOT-MRAM brings challenges in the form of too large writing current density and power dissipation . SOTMEM will validate SOT switches for SOT-MRAM using topological insulators embedded in a novel material stack that we have recently developed for optimal writing efficiency. Writing at ultralow power is therefore the key technical objective of this ERC Proof of Concept project. A successful outcome would represent a major breakthrough for SOT-MRAM commercialization. Therefore SOTMEM stands to have enormous impact in the transition towards low-power, power-fail protected microprocessors with non-volatile memories. Special efforts will be devoted to market analysis and patentability studies, as well as targeted industry engagement to allow the design of a nuanced business model aiming to deliver SOTMEM technologies and knowhow to potential end users.

Sergio Valenzuela – Institut Català de Nanociència i Nan0tecnologia (ICN2)
ERC – PoC2019

Paul Verschure · cRGS - Cognitive Rehabilitation Gamming System (cRGS): a novel Virtual Reality-based system for the conjunctive training of stroke-derived cognitive impairments

cRGS – Cognitive Rehabilitation Gamming System (cRGS): a novel Virtual Reality-based system for the conjunctive training of stroke-derived cognitive impairments
The cDAC ERC Advanced project develops and validates a theory of consciousness and its application to the understanding and alleviation of its deficits. cDAC proposes that consciousness is a virtualization memory system that monitors and optimizes the real-time control of perception, cognition and action realized in a multi-layered architecture. Building on cDAC, we have advanced and validated new concepts and methods for the diagnostics and treatment of cognitive and affective deficits post-stroke. The current PoC project will now propel these interventions into the real-world by integrating them with the Rehabilitation Gaming System (RGS), creating cRGS. cRGS will be built by the integration of several paradigms and principles underlying perception, cognition, and emotion advanced in the cDAC theory of mind. cRGS will be developed to tackle unsolved problems in diagnosis, treatment, and prevention of cognitive impairments after stroke, dementia and depression that. affect more than 400 million people worldwide creating a severe health-related burden adding up to annual costs that are measured in trillions of euros, with depression being the leading cause of disability worldwide. cRGS taps into the latest technologies such as AI, VR, big data and cloud computing to provide treatment that does not require the presence of a health professional by building on the cDAC architecture for autonomous control. cRGS solves two significant obstacles in providing healthcare namely, the lack of resources and the lack of trained professionals. Concretely, this Proof of Concept will consist of the integration of the treatment paradigms created in cDAC to treat and diagnose aphasia, cognitive impairment, and depression in one platform. This prototype will be tested in terms of usability and adherence as well as its practical use at healthcare centers and at home.

Paul Verschure – Institut  de Bioenginyeria de Catalunya (IBEC)
ERC – PoC2018

Spin-off companies


Spin-off company created in 2021

Chatbot Creation Services SL

Supported by the Universitat Oberta de Catalunya and ICREA
Entrepreneur: ICREA Research Professor Jordi Cabot
Born in June 2021


Chatbot Creation Services is a spin-off company of the Universitat Oberta de Catalunya and ICREA. It was born in 2021 to continue the development and commercialization of the open source chatbot development platform Xatkit, started at the SOM Research Lab.

Xatkit’s unique approach to chatbots and voice assistants is its focus on minimizing the effort to create them. Instead of requiring a manual definition of the bots, Xatkit is able to take whatever information is already available in the company (documents, databases,…), read it, understand it and use it to generate a first working version of the chatbot. Then, via Xatkit’s graphical interface, companies can monitor and fine-tune the bot whenever needed.

LuxQuanta Technologies SL

Supported by ICFO and ICREA
Entrepreneur: ICREA Research Professor Valerio Pruneri
Born in October 2021

LuxQuanta was born in May 2021 as a spin-off from ICFO, and after being incubated for over 4 years, with the mission of developing Quantum Key Distribution (QKD) systems. These systems can distribute cryptographic keys between users with the highest level of security as they rely on the unique properties of quantum physics instead of mathematical algorithms.

LuxQuanta uses a novel QKD technology capable of providing high-performance and cost-effective quantum cryptography solutions, easy to integrate into existing optical network infrastructures while capable of delivering a quantum-safe layer of security on top of traditional crytographic techniques.

From its headquartes in Barcelona and with solid Spanish shareholders foundations, LuxQuanta want to deliver ultra-secure data encryption and communications to all European Union’s governmental institutions, financial sectors, data centers and private telecommunication network providers for years to come

Nuage Therapeutics SL

Supported by IRB Barcelona and ICREA
Entrepreneur: ICREA Research Professor Dr. Xavier Salvatella
Born in July 2021

Nuage Therapeutics (Nuage Tx) is a spin-off company from the Institute for Research in Biomedicine (IRB Barcelona) and ICREA, that stemmed from the Laboratory of Molecular Biophysics lead by Dr. Xavier Salvatella. The company was incorporated on 29th July 2021.

The mission of Nuage Tx is to leverage biomolecular condensation and chemical biology to develop selective modulators of disordered proteins involved in challenging indications representing unmet medical needs.

Nuage Tx was founded by Xavier Salvatella, Mateusz Biesaga and Denes Hnisz, a team of scientists with complementary expertise that provide unique perspective on targeting intrinsically disordered proteins. Xavier Salvatella is an ICREA Professor and Leader of the Laboratory of Molecular Biophysics at IRB Barcelona. He is a renowned expert in intrinsically disordered proteins, biomolecular condensation and the structural properties of the transactivation domain of androgen receptor. Mateusz Biesaga is a PhD student and an MSCA fellow at the laboratory of Xavier Salvatella. He holds a degree in biomedical engineering and has expertise in assay development and validation for drug discovery. Denes Hnisz is the Leader of Precision Gene Control group at the Max Planck Institute for Molecular Genetics in Berlin (Germany). He is a prominent expert in transcriptional control, nuclear condensates and genome structure.

The first program of Nuage Tx aims to develop a potent and selective drug targeting the transactivation domain of androgen receptor to deliver a life-changing treatment to patients with castration-resistant prostate cancer. Nuage Tx is developing a proprietary Condensation Screening Assay and a Target Discovery Algorithm that will be used to identify new targets and new drug candidates. Nuage Tx aims to become a platform company with multiple assets in its pipeline.

Nuage Tx has already in-licensed a patent application from the Institute for Research in Biomedicine (IRB Barcelona) related to a proprietary in vitro condensation assay developed at Dr. Xavier Salvatella’s lab. The core intellectual property of Nuage Tx will be based on protecting the drug candidates once they reach a sufficiently advanced development stage. Other patent applications from public institutions or private entities will be in-licensed, if deemed necessary, to strengthen Nuage Tx’s patent portfolio.

Oniria Therapeutics SL

Supported by UB, VHIR and ICREA
Entrepreneur: ICREA Research Professors Gerasimos Xavier Barril
Born in December 2021

Oniria Therapeutics is a biotech company focused on the development of first-in-class drugs in the field of precision oncology. It develops therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence.

Oniria - constitució

Our flagship product, ONR-001, is an oral small molecule, first-in-class, that allosterically activates TET2, a master epigenetic enzyme, causing tumor cells to enter a dormant state and even die. ONR-001 is oncology indication agnostic and can be successfully used at all stages of the disease, from naïve primary tumors to recurrent resistant and metastatic cancer, thus “making a world of difference“.